Matthew Rossen
Director/Board Member at GARDINER HEALTHCARE ACQUISITIONS CORP.
Matthew Rossen active positions
| Companies | Position | Start | End |
|---|---|---|---|
| GARDINER HEALTHCARE ACQUISITIONS CORP. | Director/Board Member | 2021-09-30 | - |
| Independent Dir/Board Member | 2021-09-30 | - | |
| TARSUS PHARMACEUTICALS, INC. | Sales & Marketing | - | - |
Career history of Matthew Rossen
Former positions of Matthew Rossen
| Companies | Position | Start | End |
|---|---|---|---|
QED Therapeutics, Inc.
 QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Sales & Marketing | 2019-03-31 | 2021-04-30 |
| CHARDAN HEALTHCARE ACQUISITION CORP | Director/Board Member | 2018-11-30 | 2019-09-30 |
| Independent Dir/Board Member | 2018-11-30 | 2019-09-30 | |
Jazz Pharmaceuticals, Inc.
 Jazz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its medical products include xyrem, erwinaze, vyxeos, and kidrolas. The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Palo Alto, CA. | Corporate Officer/Principal | 2010-07-31 | 2019-03-31 |
| PFIZER, INC. | Corporate Officer/Principal | 2001-06-30 | 2010-06-30 |
| RENOVACOR, INC. | Director/Board Member | 2020-04-22 | - |
| Independent Dir/Board Member | 2020-04-22 | - |
Training of Matthew Rossen
| The University of Colorado | Undergraduate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Statistics
International
| United States | 10 |
Operational
| Director/Board Member | 3 |
| Independent Dir/Board Member | 3 |
| Corporate Officer/Principal | 2 |
Sectoral
| Health Technology | 5 |
| Finance | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| TARSUS PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Chardan Healthcare Acquisition Corp.
 Chardan Healthcare Acquisition Corp. Financial ConglomeratesFinance Chardan Healthcare Acquisition Corp. is a blank check company, which engages in seeking and acquiring one or more growth businesses. It focuses on businesses that have their primary operations located in North America in the healthcare industry. The company was founded on November 1 , 2017 and is headquartered in New York, NY. | Finance |
Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its medical products include xyrem, erwinaze, vyxeos, and kidrolas. The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Palo Alto, CA. | Health Technology |
Chardan Healthcare Acquisition 2 Corp.
 Chardan Healthcare Acquisition 2 Corp. Financial ConglomeratesFinance Chardan Healthcare Acquisition 2 Corp. operates as a blank check company, which engages in the acquisition of healthcare company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on December 19, 2018 and is headquartered in New York, NY. | Finance |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Health Technology |
Gardiner Healthcare Acquisitions Corp.
 Gardiner Healthcare Acquisitions Corp. Financial ConglomeratesFinance Gardiner Healthcare Acquisitions Corp. is a blank check company, which engages in merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination. The company was founded on March 25, 2021 and is headquartered in Shaker Heights, OH. | Finance |
- Stock Market
- Insiders
- Matthew Rossen
- Experience
